Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

By: via Benzinga
Shares of Bristol-Myers Squibb (NYSE: BMY ) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3. BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.